Sugi Predict

Sugi Predict / Targets / CDK11A

CDK11A

Cyclin-dependent kinase 11A · Q9UQ88 · CDK11A on Sugi Atlas →

3,228 patent compounds predicted against CDK11A, 2,147 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5726371 SCHEMBL5726371 0.80 19/20
SCHEMBL5726896 SCHEMBL5726896 0.75 19/20
SCHEMBL5725742 SCHEMBL5725742 1.00 18/20
SCHEMBL5726914 SCHEMBL5726914 0.85 18/20
SCHEMBL5725980 SCHEMBL5725980 0.82 18/20
SCHEMBL5726816 SCHEMBL5726816 0.75 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL5725424) 0.63 18/20
SCHEMBL5724944 SCHEMBL5724944 1.00 17/20
SCHEMBL5726610 SCHEMBL5726610 1.00 17/20
SCHEMBL5725215 SCHEMBL5725215 0.93 17/20
SCHEMBL5726996 SCHEMBL5726996 0.77 17/20
SCHEMBL5725321 SCHEMBL5725321 0.73 17/20
SCHEMBL5725970 SCHEMBL5725970 0.68 17/20
SCHEMBL5726435 SCHEMBL5726435 0.82 16/20
SCHEMBL5726324 SCHEMBL5726324 0.82 16/20
SCHEMBL5725351 SCHEMBL5725351 0.78 16/20
SCHEMBL5724762 SCHEMBL5724762 0.77 16/20
SCHEMBL5724764 SCHEMBL5724764 0.77 16/20
SCHEMBL5725771 SCHEMBL5725771 0.77 16/20
SCHEMBL5725641 SCHEMBL5725641 0.74 16/20

Clinical trials — most relevant to CDK11A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer PHASE2UNKNOWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations PHASE2COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors PHASE1/PHASE2COMPLETED
Genetic Testing in Guiding Treatment for Patients With Brain Metastases PHASE2ACTIVE_NOT_RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies PHASE1RECRUITING
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK11A binder may also engage these)

ProteinNameSimilarity
P24788 — 1.000 P24788 →
CDK11B Cyclin-dependent kinase 11B 1.000 landscape →
Q7XUF4 — 0.990 Q7XUF4 →
A2XUW1 — 0.986 A2XUW1 →
Q9VPC0 — 0.985 Q9VPC0 →
Q6K5F8 — 0.985 Q6K5F8 →
A2X6X1 — 0.983 A2X6X1 →
Q80TJ7 — 0.980 Q80TJ7 →
Q61136 — 0.980 Q61136 →
E1BTG2 — 0.980 E1BTG2 →
Q80XC3 — 0.979 Q80XC3 →
PRP4K Serine/threonine-protein kinase PRP4 homolog 0.979 landscape →
Q5RKH1 — 0.979 Q5RKH1 →
P32023 — 0.979 P32023 →
PRPF40A Pre-mRNA-processing factor 40 homolog A 0.979 landscape →
Q9R1C7 — 0.979 Q9R1C7 →
Q3SXY8 — 0.978 Q3SXY8 →
Q08DZ2 — 0.978 Q08DZ2 →
Q8C5N3 — 0.978 Q8C5N3 →
Q9FGW5 — 0.978 Q9FGW5 →
Q9BZI7 — 0.978 Q9BZI7 →
Q53F19 — 0.978 Q53F19 →
Q9WVR4 — 0.977 Q9WVR4 →
Q498F0 — 0.977 Q498F0 →
Q09437 — 0.977 Q09437 →
KAT2B Histone acetyltransferase KAT2B 0.977 landscape →
Q5RHD1 — 0.977 Q5RHD1 →
Q8BZR9 — 0.977 Q8BZR9 →
P51115 — 0.976 P51115 →
Q3UQU0 — 0.976 Q3UQU0 →